http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 송무곤 ( Moo Gon Song ) (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
감염 ; 우리나라 사람면역결핍바이러스 감염 환자에서 악성종양 발생 양상
설영미 ( Young Mi Seol ),송무곤 ( Moo Gon Song ),최영진 ( Young Jin Choi ),이선희 ( Sun Hee Lee ),김성일 ( Sung Il Kim ),정주섭 ( Joo Seop Chung ),곽임수 ( Ihm Soo Kwak ),조군제 ( Goon Jae Cho ),이혁 ( Hyuck Lee ),정동식 ( Dong S 대한내과학회 2009 대한내과학회지 Vol.76 No.5
목적: 항HIV 치료의 발전으로 HIV 환자가 장기간 생존하게 되면서 악성종양은 HIV 환자에서 중요한 사망원인으로 대두되고 있다. 본 연구는 국내 HIV 환자에서 암 발생양상을 알아보고 이전에 발표된 국내의 연구들과 비교해봄으로서 우리나라 HIV 환자에서 발생하는 암 발생 특성을 파악하는데 도움이 되는 자료를 제시하고자 하였다. 방법: 1990년 1월부터 2008년까지 6월까지 부산지역 4개 대학 병원(고신대병원, 동아대병원, 부산대병원, 인제대병원)에 내원하였던 HIV 감염 환자들을 대상으로 의무기록을 후향적으로 분석하였다. 결과: 대상 환자 683명 중 27명(4%)에서 악성종양이 발생하였다. 27명 중에서 남자는 25명(93%)이었고, 악성종양 진단 시점 연령의 중앙값(범위) 48세(24~76세)였다. 진단 당시 평균 CD4+ 세포수의 중앙값(범위)은 42/uL (3~399)이었다. 비에이즈 정의 악성종양이 14예(52%), 에이즈 정의 악성종양 13예(48%)였다. 시기별로는 Pre-HAART 기간에는 에이즈 정의 악성종양과 비이에즈 정의 악성종양이 각각 2예씩 발생하였고, HAART 기간에는 비에이즈 정의 악성종양이 12예(52%)로 에이즈 정의 악성종양 11예(48%)가 발생하였다. 에이즈 정의 악성종양 중에서는 비호지킨 림프종(9/13)이 가장 많았고, 카포시육종(4/13)의 순이었다. 비호지킨 림프종 중에서는 미만성 B형 대세포 림프종이 가장 많았으며(5/9) 중추신경계 미만성 B형 대세포 림프종 (3/9), 버킷 림프종 (1/9)의 순이었다. 비에이즈 정의 악성종양 중에서는 위암, 직장암, 간세포암이 가장 많았으며(각각 3/14) 그 외 갑상선암, 편도암, 식도암, 혈관육종, 에크린 땀샘암종(eccrine carcinoma)이 각각 1예로, 위장관 기원 악성종양이 50% (7/14)를 차지하였다. 에이즈 정의 악성종양과 비에이즈 정의악성종양 발생 환자의 사이에는 내원 시점 CD4+ 세포수 중앙값은 각각 18, 114/uL로 비에이즈 정의 악성종양 환자에서 의미있게 높았다(p=0.001). 그 외에 성별, 전파경로, HBsAg 양성, 진단 시점 연령, 사망여부, HIV 감염에서 악성종양 진단까지 및 첫 내원부터 악성종양 진단까지 기간은 양 군 간에 의미있는 차이가 없었다. 결론: 국내 HIV 감염 환자의 악성 종양 발병률은 4%였다. 항HIV 치료에 의한 생존율의 향상에 따른 에이즈 악성종양의 감소와 비에이즈 정의 악성종양의 상대적 증가 양상은 관찰되지 않았다. 가장 흔한 악성종양은 비호지킨 림프종이었으며 비에이즈 악성종양 중에서는 소화기계통의 악성종양과 간암이 흔히 발생하였다. Background/Aims: The prevalence of malignancies associated with human immunodeficiency virus (HIV) is rapidly increasing. The aim of the present study was to identify clinical features associated with malignancies in South Korean patients infected with HIV. Methods: From January 1990 to June 2007, we reviewed an electronic database containing pathological reports obtained from HIV-infected patients and then retrospectively analyzed a total of 27 malignancy cases treated at four different institutions. Results: Among 683 patients infected with HIV, malignant diseases were diagnosed in 27 cases (4.0%). Twenty-five of these patients were male, and the median age was 48 (range; 24-76). At the time of diagnosis, the median CD4+ lymphocyte count was 42/uL (range 3-339). Acquired immune deficiency syndrome (AIDS)-defining malignancies were diagnosed in 13 patients (48%) and non-AIDS-defining malignancies were diagnosed in 14 patients (52%). Two patients each were diagnosed with AIDS-defining and non-AIDS-defining malignancies during the pre-highly active anti-retroviral therapy (HARRT) period. In contrast, 11 patients (48%) and 12 patients (52%) were diagnosed with AIDS-defining and non-AIDS-defining malignancies during the HARRT period, respectively. Among AIDS-defining malignancies, non-Hodgkins lymphoma was the most frequently observed (9/13), followed by Kaposi`s sarcoma (4/13). Among the 9 patients with non-Hodgkins lymphoma, diffuse large B-cell lymphoma was most common (5/9), followed by primary CNS lymphoma (3/9) and Burkitt`s lymphoma (1/9). Gastrointestinal (GI) malignancies [i.e., gastric cancer (3/14), rectal cancer (3/14), and esophageal cancer (1/14)] and hepatocellular carcinoma (3/14) were the most commonly observed among the non-AIDS-defining malignancies. Other observed non-AIDS-defining malignancies were thyroid cancer (1/14), tonsillar cancer (1/14), angiosarcoma (1/14), and eccrine cancer (1/14). Finally, median CD4+ lymphocyte counts at the time of diagnosis were significantly different (18 vs. 114/uL, p=0.001) between AIDS-defining malignancies and non-AIDS-defining malignancies. Conclusions: Malignancies were diagnosed in 4.0% of patients infected with HIV. This study showed similar rates of incidence between AIDS-defining and non-AIDS-defining malignancies. Non-Hodgkins lymphoma was the most frequently observed malignancy, whereas GI malignancies and hepatocellular carcinoma were common among non-AIDS-defining malignancies. (Korean J Med 76:554-563, 2009)
-
간세포암의 횡격막 전이에 의해 발생한 복막투석액의 흉강누출
안용성 ( Yong Sung Ahn ),강진 ( Jin Kang ),송무곤 ( Moo Gon Song ),박기태 ( Ki Tae Park ),박태익 ( Tae Ik Park ),안승재 ( Seung Jae Ahn ),송상헌 ( Sang Heon Song ),이동원 ( Dong Won Lee ),이수봉 ( Soo Bong Lee ),곽임수 ( Ihm Soo 대한신장학회 2006 Kidney Research and Clinical Practice Vol.25 No.5
Massive hydrothorax is uncommon but well recognized complication of peritoneal dialysis. Possible mechanisms include a disorder of lymphatic drainage, pleuro-peritoneal pressure gradient, and congenital diaphragmatic defects. Hydrothorax in a CAPD patient caused by infiltrative disease or malignancy is very rare. Recently, two cases of hydrothorax in CAPD patients caused by systemic amyloidosis involving diaphragm were reported. However, no case of pleuro-peritoneal communication secondary to HCC infiltrating diaphragm was reported. This case was of a hydrothorax due to HCC in a CAPD patient. We performed video-assited thoracoscopic resection of diaphragmatic mass, diaphragmatic repair and thoracoscopic talc pleurodesis. This case showed that malignancy might be considered as a cause of a hydrothorax in a CAPD patient. (Korean J Nephrol 2006;25(5):851-855)
-
-
국소 진행성 두경부암의 S-1과 Cisplatin의 유도 화학요법
정주섭,최영진,설영미,송무곤,신호진,조군제 부산대학교 병원 암연구소 2008 부산대병원학술지 Vol.- No.23
Objective: This study was performed to assess the efficacy and safety profiles of the combination treatment with S-1 and Cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Design: Eligibility criteria consisted of histologically confirmed SCCHN, stage III or IV with no evidence of distant metastasis, evaluable lesions, adequate organ function, age of 20-80 years, and a performance status of 2 or less. Cisplatin was infused over 1 hour on day 1 (75 mg/m²) and S-1 was administered orally for 14 consecutive days (days 2-15). The dosages of S-1 were assigned according to the patients' body surface area (BSA): 50 mg twice a day (B5A<1.5m²),or 60 mg twice a day (B5A>1.5m²). Each course was repeated every 3 weeks. After 2 courses, tumor response was evaluated by CT scan and laryngoscopy. If the patients achieved a response (complete response: CR, or partial response: PR), they received one more course of chemotherapy before undergoing radical treatment such as radiotherapy or operation. Results: All 30 patients were assessable for toxicity, and 29 patients for response. Theoverall response was 89.7 % (CR:9, PR:17). 2 year estimated overall survival rate was 79.2 %. Adverse reactions occurred 128 times during 81 courses in the 30 cases. The most common grade 3/4 adverse event was neutropenia, which occurred in 8 patients. Non-hematological grade 3 or 4 toxicity included nausea and vomiting in 4 patients, stomatitis in 2 patients, and diarrhea in 1 patient. Conclusion: S-1 plus cisplatin combination chemotherapy is effective against locally advanced SCCHN with mild toxicity.
KCI
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
